Clinical Trials Browser

Phase 3 × Lymphoma, Non-Hodgkin × Inotuzumab Ozogamicin × Clear all

NCT01232556 2019-01-08

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Phase 3 Terminated

338 enrolled 15 charts

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse